CORPUS CHRISTI, Texas, Oct. 10 /PRNewswire-FirstCall/ -- CSMG Technologies, Inc., (OTC Bulletin Board: CTGI), a technology management company, announced the company has received approval of its fifth U.S. patent. The approval is on a key divisional application for "Bonding of Soft Biological Tissues by Passing High Frequency Electric Current Therethrough" for CSMG Technologies subsidiary Live Tissue Connects ("LTC") platform tissue bonding/welding technology. The patent approval follows the issuance of four other U.S. patents, a European Union patent, in eight European countries, Ukraine, Canada and Australia with 14 U.S. and international patents pending.
Donald S. Robbins, President and CEO of CSMG Technologies, said, "This key U.S. patent approval re-enforces our patent portfolio and expands LTC's commercial possibilities while increasing our shareholder value. Our strong patent portfolio, and a disruptive technology as well as ISO 13485:2003 certification for the design and manufacture of Bipolar Forceps Systems, recent US FDA 510(k) clearance and European Union C. E. Mark certification on LTC's VAD.400 electrosurgery generator and two instruments puts us in an excellent position of competing in global medical device markets."
"Our LTC team has presented comparative results at conferences with the LTC bipolar sealing system and shown that LTC's bipolar sealing system has broad applications. Additionally, in preparation for launching LTC's commercial product I early 2009, LTC has begun building inventory for both LTC's electro surgery generator and hand instrument for duct and vessel sealing, and are in discussions with interested international medical device companies and distributors," Mr. Robbins added.
About Live Tissue Connect
LTC's surgical tissue bonding / welding device is a patented platform technology that bonds and reconnects human soft tissue through fusion, in contrast with conventional wound closing devices such as sutures, staples, sealant, or glues. LTC currently holds a total of approximately 31 patents and pending patents in the U.S., Australia, Canada, European Union, Ukraine and other countries.
For further information on Live Tissue Connect, please visit the LTC website at http://www.livetissueconnect.com.
For further information on CSMG Technologies and its various subsidiaries, please visit our website at http://www.csmgtechinternational.com.
Sign up to receive CSMG Technologies automated email press releases and other notifications: Please go to: http://www.csmgtechinternational.com/contact_information.html and fill-in information.
This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934 as amended (the Exchange Act), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the company, its directors or its officers with respect to, among other things: (i) the company's financing plans; (ii) trends affecting the company's financial condition or results of operations; (iii) the company's growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend" and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors.
|SOURCE CSMG Technologies, Inc.|
Copyright©2008 PR Newswire.
All rights reserved